Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

• Status: Active, not recruiting
• Trial end date: 2022-06-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Dacarbazine; Doxorubicin; Liposomal doxorubicin; Nivolumab; Vinblastine

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C - enrollment closed)

• Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B & C - enrollment closed)

• Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

Exclusion Criteria:

• Known central nervous system lymphoma

• Participants with nodular lymphocyte-predominant Hodgkin Lymphoma

• Prior allogeneic stem cell transplantation (SCT)

• Chest radiation ≤ 24 weeks prior to first dose

• Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen